title: [The value of active stents for coronary angioplasty in patients with chronic renal failure].
abstract: The risk of intra-stent restenosis has diminished considerably with the advent of endoprostheses which actively release sirolimus or paclitaxel. Patients with chronic renal failure constitute a high cardiovascular risk population, in whom the incidence of coronary heart disease is particularly high, representing one of the principal causes of death. The aim of this study, which included 152 patients, was to quantify the value of active stents for coronary angioplasty in patients with chronic renal failure. Thirty eight patients with chronic renal failure who underwent angioplasty with active stents were matched for age, sex and the presence of diabetes with 3 other groups of patients: one group with active stents but without renal failure, one group with inactive stents and no renal failure, and one group with inactive stents and chronic renal failure. The average follow up was 16 +/- 5 months. The acute stent thrombosis rate (2%) was not elevated in cases of renal failure nor after active stent implantation. Chronic renal failure significantly increased the mortality rate 16 months after angioplasty, whichever type of stent was used: 8 versus 2% deaths in patients with an inactive stent (p = 0.001). In renal failure, the risk of death was lower with an active stent (8 vs 26% with an inactive stent, p<0.05). Similarly, there was a non-significant trend towards a lower risk of death and/or infarction in renal failure after active stents (8 vs 21% with an inactive stent, NS).
  
  
  CONCLUSIONS
  In this study, coronary angioplasty with an active stent in patients with chronic renal failure was associated with a lower mortality rate compared with inactive stents, with no increase in the risk of acute thrombosis.
authors.affiliation: AP-HP, département de cardiologie médicale, institut de cardiologie, groupe hospitalier la Pitié-Salpêtrière, Paris.
authors.forename: G
authors.initials: G
authors.lastname: Phélippeau
authors.forename: C
authors.initials: C
authors.lastname: Le Feuvre
authors.forename: G
authors.initials: G
authors.lastname: Helft
authors.forename: F
authors.initials: F
authors.lastname: Beygui
authors.forename: J P
authors.initials: JP
authors.lastname: Collet
authors.forename: R
authors.initials: R
authors.lastname: Choussat
authors.forename: G
authors.initials: G
authors.lastname: Montalescot
authors.forename: J P
authors.initials: JP
authors.lastname: Metzger
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015607:Stents